

NEW USE OF PYRIMIDINE - OR TRIAZINE-2-CARBONITILES FOR TREATING DISEASES  
ASSOCIATED  
WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES


The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors.

### BACKGROUND OF THE INVENTION

Cathepsin S is a member of the papain superfamily of cysteine proteases which also encompasses Cathepsins B, H, L, O and K. Cathepsin S plays a key role in the processing of invariant chain in MHC class II complexes allowing the complex to associate with antigenic peptides. MHC class II complexes are then transported to the surface of the cell for presentation to effector cells such as T cells. The process of antigen presentation is a fundamental step in initiation of the immune response. In this respect inhibitors of cathepsin S could be useful agents in the treatment of inflammation and immune disorders such as, but not limited to, asthma, rheumatoid arthritis, multiple sclerosis and Crohn's disease. Cathepsin S has also been implicated in a variety of other diseases involving extracellular proteolysis such as the development of emphysema in COPD through degradation of elastin and in Alzheimers disease.

Other Cathepsins notably K and L have been shown to degrade bone collagen and other bone matrix proteins. Inhibitors of these cysteine proteases would be expected to be useful in the treatment of diseases involving bone resorption such as osteoporosis.

The present invention therefore provides use of a compound of formula (I)



(I)

in which:

X is N or CA where A is hydrogen, halogen,  $\text{CHR}^2\text{R}^3$ ,  $\text{OR}^2$ ,  $\text{NR}^2\text{R}^3$ ,  $\text{SR}^2$ ;

5  $\text{R}^2$  and  $\text{R}^3$  are independently hydrogen,  $\text{C}_{1-6}$  alkyl or  $\text{C}_{3-6}$  cycloalkyl both of which can optionally contain one or more O, S or  $\text{NR}^4$  groups where  $\text{R}^4$  is hydrogen or  $\text{C}_{1-6}$  alkyl, and can be optionally substituted by aryl, heteroaryl,  $\text{NR}^5\text{R}^6$  where  $\text{R}^5$  and  $\text{R}^6$  together with the nitrogen atom to which they are attached form a 4-7 membered ring optionally containing a  
10 further O, S,  $\text{NR}^4$ , or R2 and R3 together with the nitrogen atom to which they are attached form a 4-7 membered ring optionally containing a further O, S,  $\text{NR}^4$  group, or R2 and R3 are aryl or heteroaryl groups, both aryl and heteroaryl groups being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy,  $\text{CONR}^7\text{R}^8$ ,  $\text{SO}_2\text{NR}^7\text{R}^8$ ,  $\text{SO}_2\text{R}^4$ , trifluoromethyl,  $\text{NHSO}_2\text{R}^4$ ,  $\text{NHCOR}^4$ , ethylenedioxy, methylenedioxy,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$   
15 alkoxy,  $\text{NR}^7\text{R}^8$  or  $\text{SR}^7$  where  $\text{R}^7$  and  $\text{R}^8$  are independently hydrogen or  $\text{C}_{1-6}$  alkyl;

R and  $\text{R}^1$  are independently a group  $\text{Y}(\text{CH}_2)_p\text{R}^9$  where p is 0, 1, 2 or 3 and Y is O or  $\text{NR}^{10}$  where  $\text{R}^{10}$  is hydrogen,  $\text{C}_{1-6}$  alkyl or  $\text{C}_{3-6}$  cycloalkyl;  
and  $\text{R}^9$  is hydrogen,  $\text{C}_{1-6}$  alkyl which can optionally contain one or more O, S or  $\text{NR}^4$   
20 groups where  $\text{R}^4$  is hydrogen or  $\text{C}_{1-6}$  alkyl, or a 3 to 7-membered saturated ring optionally containing a carbonyl group, one or more O, S or N atoms, or an aryl or heteroaryl group containing one to four heteroatoms selected from O, S or N, the saturated ring, aryl and heteroaryl groups all being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy,  $\text{CONR}^7\text{R}^8$ ,  $\text{SO}_2\text{NR}^7\text{R}^8$ ,  $\text{SO}_2\text{R}^4$ , trifluoromethyl,  $\text{NHSO}_2\text{R}^4$ ,  $\text{NHCOR}^4$ ,  
25 ethylenedioxy, methylenedioxy,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy,  $\text{SR}^5$  or  $\text{NR}^{11}\text{R}^{12}$  where  $\text{R}^{11}$  and  $\text{R}^{12}$  are independently hydrogen,  $\text{C}_{1-6}$  alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or  $\text{NR}^4$  group;  
or  $\text{R}/\text{R}^1$  is a group  $\text{NR}^{10}(\text{CHR}^{10})\text{CONR}^2\text{R}^3$  or  $\text{NR}^{10}(\text{CH}_2)_q\text{CONR}^2\text{R}^3$  where q is 1, 2 or 3;  
30 or  $\text{R}/\text{R}^1$  is a group  $\text{NR}^{13}\text{R}^{14}$  where  $\text{R}^{13}$  and  $\text{R}^{14}$  together with the nitrogen atom to which they are attached form a 4 to 7-membered saturated ring optionally containing a carbonyl group, O, S or N atom and optionally substituted by  $\text{C}_{1-6}$  alkyl, amino, hydroxy,  $\text{CO}_2\text{C}_{1-6}$  alkyl, halogen,  $\text{NR}^5\text{R}^6$ ,  $\text{NR}^7\text{R}^8$ ,  $\text{C}_{1-6}$  alkyl $\text{NR}^{17}\text{R}^{18}$  where  $\text{R}^{17}$  and  $\text{R}^{18}$  are independently hydrogen or  $\text{C}_{1-6}$  alkyl,  $\text{CONR}^{15}\text{R}^{16}$  where  $\text{R}^{15}$  and  $\text{R}^{16}$  are independently hydrogen or  $\text{C}_{1-6}$   
35 alkyl, or optionally substituted by aryl, phenoxy, Cophenyl, or a heteroaryl group, the latter four groups being optionally substituted by halogen, amino, hydroxy, cyano, nitro,

carboxy,  $\text{CONR}^7\text{R}^8$ ,  $\text{SO}_2\text{NR}^7\text{R}^8$ ,  $\text{SO}_2\text{R}^4$ , trifluoromethyl,  $\text{NHSO}_2\text{R}^4$ ,  $\text{NHCOR}^4$ , ethylenedioxy, methylenedioxy,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy,  $\text{SR}^5$  or  $\text{NR}^{11}\text{R}^{12}$  where  $\text{R}^{11}$  and  $\text{R}^{12}$  are independently hydrogen,  $\text{C}_{1-6}$  alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or  
5  $\text{NR}^4$  group;

and pharmaceutically acceptable salts or solvates thereof, in the manufacture of a medicament for use in the inhibition of cathepsin S in a mammal such as man.

10 In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Aryl groups include phenyl and naphthyl. Heteroaryl groups include 5- or 6- membered, 5,6- or 6,6-fused heterocyclic rings containing one or more heteroatoms selected from N, S, O. Examples include pyridine, pyrimidine, thiazole, oxazole, pyrazole, imidazole, furan,  
15 thiophene, quinoline, isoquinoline, benzimidazole, benzofuran, benzothiophene and indole.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and  
20 mixtures thereof also form an aspect of the present invention.

Preferably X is CH,  $\text{NHR}^2$ ,  $\text{OR}^2$  where  $\text{R}^2$  is preferably H or  $\text{C}_{1-6}$  alkyl.

Preferably R is a group  $\text{Y}(\text{CH}_2)_p\text{R}^7$  where p is 0 or 1 and Y is  $\text{NR}^8$  where  $\text{R}^8$  is hydrogen  
25 and  $\text{R}^7$  is substituted phenyl. Preferably  $\text{R}^7$  is phenyl substituted by halogen, especially chloro. More preferably  $\text{R}^7$  is phenyl substituted by chloro in the 4-position.

Preferably  $\text{R}^1$  is a group  $\text{NR}^{13}\text{R}^{14}$  where  $\text{R}^{13}$  and  $\text{R}^{14}$  together with the nitrogen atom to which they are attached form a morpholine ring, piperidine or piperazine ring optionally  
30 substituted, or  $\text{R}^1$  is a group  $\text{NR}^9\text{R}^{10}$  where  $\text{R}^{10}$  is H or  $\text{C}_{1-6}$  alkyl and  $\text{R}^9$  is  $\text{C}_{1-6}$  alkyl which can optionally contain one or more O, S or  $\text{NR}^4$  groups where  $\text{R}^4$  is hydrogen or  $\text{C}_{1-6}$  alkyl.

The most preferred substituents for R and  $\text{R}^1$  are those of the examples exemplified herein.

35 Preferred compounds of the invention include:  
4-[(4-Chlorophenyl)amino]-6-(dimethylamino)-1,3,5-triazine-2-carbonitrile,


- 4-Morpholin-4-yl-6-(4-phenoxy piperidin-1-yl)-1,3,5-triazine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile,  
4-(7-Azabicyclo[2.2.1]hept-7-yl)-6-[(4-chlorophenyl)amino]-1,3,5-triazine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazine-2-carbonitrile,  
5 4-[(4-Chlorophenyl)amino]-6-piperidin-1-yl-1,3,5-triazine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-(ethylamino)-1,3,5-triazine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-(3-hydroxypyrrolidin-1-yl)-1,3,5-triazine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-[(2-piperidin-1-ylethyl)amino]-1,3,5-triazine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-(4-phenylpiperidin-1-yl)-1,3,5-triazine-2-carbonitrile,  
10 4-[(3-Chlorobenzyl)amino]-6-(dimethylamino)-1,3,5-triazine-2-carbonitrile,  
4-Morpholin-4-yl-6-[(4-morpholin-4-ylphenyl)amino]-1,3,5-triazine-2-carbonitrile,  
4-(2,3-Dihydro-1,4-benzodioxin-6-ylamino)-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile,  
4-Morpholin-4-yl-6-(3-phenylpiperidin-1-yl)-1,3,5-triazine-2-carbonitrile,  
15 4-(1,4'-Bipiperidin-1'-yl)-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile,  
4-[4-(1H-Imidazol-1-yl)piperidin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile,  
4-[4-(4-Chlorobenzoyl)piperidin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile,  
4-[4-(5-Chloropyridin-2-yl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile,  
4-Morpholin-4-yl-6-{[3-(2-oxopyrrolidin-1-yl)propyl]amino}-1,3,5-triazine-2-carbonitrile,  
20 1-(4-Cyano-6-morpholin-4-yl-1,3,5-triazin-2-yl)-N,N-diethylpiperidine-3-carboxamide,  
4-[4-(2-Methoxyphenyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile,  
N~2~(4-Cyano-6-morpholin-4-yl-1,3,5-triazin-2-yl)-N~1~,N~1~-bis{4-[N-(4-cyano-6-morpholin-4-yl-1,3,5-triazin-2-yl)-N-isobutylglycyl]morpholin-3-yl}-N~2~-isobutylglycinamide,  
25 4-Morpholin-4-yl-6-[(2-pyridin-3-ylethyl)amino]-1,3,5-triazine-2-carbonitrile,  
4-[[2-(2-Furyl)ethyl]amino]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-(4-methylpiperazin-1-yl)-1,3,5-triazine-2-carbonitrile,  
4-Azetidin-1-yl-6-[(4-chlorophenyl)amino]-1,3,5-triazine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile,  
30 4-[(4-Methylcyclohexyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile,  
4-(4-Chlorophenoxy)-6-morpholin-4-ylpyrimidine-2-carbonitrile,  
4-[(4-Chlorophenyl)amino]-6-(dimethylamino)pyrimidine-2-carbonitrile,  
4-[(1-Methylpiperidin-4-yl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile,  
4-(Cyclohexylamino)-6-morpholin-4-ylpyrimidine-2-carbonitrile,  
35 4-[(4-Chlorophenyl)amino]-6-pyrrolidin-1-ylpyrimidine-2-carbonitrile,  
4-[(6-Chloropyridin-3-yl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile,

1-{6-[(4-Chlorophenyl)amino]-2-cyanopyrimidin-4-yl}-L-prolinamide,  
 4-(4-Aminopiperidin-1-yl)-6-[(4-chlorophenyl)amino]pyrimidine-2-carbonitrile,  
 4-[(4-Chlorophenyl)amino]-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidine-2-carbonitrile,  
 4-[(4-Chlorophenyl)amino]-6-[(3-pyrrolidin-1-ylpropyl)amino]pyrimidine-2-carbonitrile,  
 5 tert-Butyl 4-{6-[(4-chlorophenyl)amino]-2-cyanopyrimidin-4-yl}piperazine-1-carboxylate,  
 4-[(4-Chlorophenyl)amino]-6-(cyclopropylamino)pyrimidine-2-carbonitrile,  
 4-[(4-Chlorophenyl)amino]-6-piperazin-1-ylpyrimidine-2-carbonitrile,  
 (2S)-N~2~-{6-[(4-Chlorophenyl)amino]-2-cyanopyrimidin-4-yl}-N~1~,N~1~-bis[4-(N-  
 {6-[(4-chlorophenyl)amino]-2-cyanopyrimidin-4-yl}-L-leucyl)morpholin-3-yl]-L-  
 10 leucinamide,  
 5-Chloro-4-[(4-chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile,  
 4-[(4-Chlorophenyl)amino]-5-methoxy-6-piperazin-1-ylpyrimidine-2-carbonitrile,  
 4-[(4-Chlorophenyl)amino]-5-methoxy-6-morpholin-4-ylpyrimidine-2-carbonitrile,  
 4-[(3S)-3-Aminopyrrolidin-1-yl]-6-[(4-chlorophenyl)amino]-5-methoxypyrimidine-2-  
 15 carbonitrile,  
 4-[(4-Chlorophenyl)amino]-6-{4-[3-(dimethylamino)propyl]piperazin-1-yl}-5-  
 methoxypyrimidine-2-carbonitrile,  
 4-[(4-Chlorophenyl)amino]-6-(dimethylamino)-5-methoxypyrimidine-2-carbonitrile,  
 4-[(4-Chlorophenyl)amino]-5-methoxy-6-(3-oxopiperazin-1-yl)pyrimidine-2-carbonitrile,  
 20 1-{6-[(4-Chlorophenyl)amino]-2-cyano-5-methoxypyrimidin-4-yl}piperidine-3-  
 carboxamide,  
 4-(4-Aminopiperidin-1-yl)-6-[(4-chlorophenyl)amino]-5-methoxypyrimidine-2-  
 carbonitrile,  
 5-Amino-4-[(4-chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile,  
 25 5-Amino-4-[(4-Chlorophenyl)amino]-6-(ethylamino)pyrimidine-2-carbonitrile,  
 and pharmaceutically acceptable salts thereof.

In a further aspect the invention provides a compound of formula (I) as defined above but  
 where X is CH,  $\text{NHR}^2$ ,  $\text{OR}^2$  where  $\text{R}^2$  is preferably H or  $\text{C}_{1-6}$  alkyl. For the novel  
 30 compounds of the invention other preferred groups and compounds are those defined  
 above.

The present invention further provides a process for the preparation of a compound of  
 formula (I) which comprises


(i) reaction of a compound of general formula (II)




wherein L1, L2 and L3 represent a leaving group (e.g. halide, sulphide, sulfoxide or sulphone group), preferably the sulphide is oxidised to a sulfoxide or sulphone group before displacement. An oxidising agent such as a peracid may be used, for example meta-chloroperoxybenzoic acid in dichloromethane at room temperature.

L1 and L2 may be displaced by R and R<sup>1</sup> respectively where R and R<sup>1</sup> are defined in formula (I) and L3 may be displaced by a cyanide salt. The sequence of displacement of L1, L2 and L3 may be varied.


When X=CA and A= OR<sup>2</sup>, SR<sup>2</sup> or CHR<sup>2</sup>R<sup>3</sup> compounds of general formula (II) may be formed by treatment of compounds of general formula (III) and (IV) with phosphorous oxychloride at reflux. R<sup>19</sup> is preferably C<sub>1-6</sub> alkyl or benzyl



(III)



(IV)



(V)

(ii) when X=CA and A=NH<sub>2</sub> reaction of a compound of general formula (V) under a hydrogen atmosphere with palladium catalyst at room temperature.

According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use as a therapeutic agent.

According to a further feature of the present invention there is provided a method for producing inhibition of a cysteine protease in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.

5

The invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament; and the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of a cysteine protease in a warm blooded animal, such as man. In particular the compounds of the invention are useful in the treatment of inflammation and immune disorders such as asthma, rheumatoid arthritis, COPD, multiple sclerosis, Crohn's disease, Alzheimers and pain, such as neuropathic pain. Preferably the compounds of the invention are used to treat pain, in particular neuropathic pain.

15

In particular the invention provides the use of a compound of the formula (I) of the present invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the inhibition of Cathepsin S in a warm blooded animal, such as man. In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment of mammals including humans, in particular in the inhibition of a cysteine protease, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

20

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.

25

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.

30  
35

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 100 mg and 1 g of the compound of this invention.

- 5 In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of  $1 \text{ mgkg}^{-1}$  to  $100 \text{ mgkg}^{-1}$  of the compound, preferably in the range of  $5 \text{ mgkg}^{-1}$  to  $20 \text{ mgkg}^{-1}$  of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically-acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:



(a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X.	100
Lactose Ph.Eur.	179
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur.	229
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

5 (c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur.	92
Croscarmellose sodium	4.0
Polyvinylpyrrolidone	2.0
Magnesium stearate	1.0

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.

(e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl  $\beta$  cyclodextrin may be used to aid formulation.

5 Note

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

10 The following examples illustrate the invention.

**Example 1****4-[(4-Chlorophenyl)amino]-6-(dimethylamino)-1,3,5-triazine-2-carbonitrile****5 (i) 4,6-Dichloro-N-(4-chlorophenyl)-1,3,5-triazin-2-amine**

4-Chloroaniline (8.28g) was added to a mixture of trichlorotriazine (6g) in acetone/ice-water (1:1, 60ml) and stirred for 1h. The solid was filtered off and dried to give a light brown solid, 8.5g.

10 MS: APCI(+ve) 275/7(M+1)

**(ii) 6-Chloro-N-(4-chlorophenyl)-N,N-dimethyl-1,3,5-triazine-2,4-diamine**

A solution of dimethylamine in tetrahydrofuran (2M, 1.1ml) was added to a mixture of the product from step (i) (0.3g) in acetone (10ml) and ice-water (10ml). After stirring for 1h,  
15 the solid was filtered, washed with water and dried. Yield 0.3g solid.

MS: APCI(+ve) 284(M+1)

**(iii) 4-[(4-Chlorophenyl)amino]-6-(dimethylamino)-1,3,5-triazine-2-carbonitrile**

20 Sodium cyanide (0.138g) was added to a solution of the product from step (ii) (0.4g) in N,N-dimethylformamide (20ml) and heated at 90°C for 16h. The mixture was partitioned between ethyl acetate and water, a solid formed which was filtered off and purified by RPHPLC 15-85% acetonitrile in aqueous trifluoroacetic acid. Yield 0.05g

25 MS: APCI(+ve) 275(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.30(1H, bs), 7.72-7.37(4H, 2xd), 3.14(6H, s)

**Example 2****4-Morpholin-4-yl-6-(4-phenoxy piperidin-1-yl)-1,3,5-triazine-2-carbonitrile**

30

**(i) 2,4-Dichloro-6-morpholin-4-yl-1,3,5-triazine**

Morpholine was added dropwise to stirred solution of trichlorotriazine (6.7g), N,N-diisopropylethylamine (6.5ml) in dichloromethane (50ml) at -78°C. The solid formed was filtered off, washed with water, dried to give a white solid (6.7g).

35

MS: APCI(+ve) 235(M+1)

**(ii) 4-Morpholin-4-yl-6-(4-phenoxy piperidin-1-yl)-1,3,5-triazine-2-carbonitrile**

4-Phenoxy piperidine (0.15g) was added to a solution of the product from step (i) (0.2g), N,N-diisopropylethylamine (1.47ml) in tetrahydrofuran and stirred at room temperature for 16h. The solvent was evaporated under reduced pressure and the residue purified by chromatography on silica eluting with ether/isohexane (1:2). Yield 0.3g white solid. The solid was dissolved in N,N-dimethylformamide (20ml), sodium cyanide (0.1g) added and heated at 90°C for 32h. The mixture was partitioned between ethyl acetate and water, the organic layer separated, washed with water, brine, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by RPHPLC 35-95% acetonitrile in aqueous trifluoroacetic acid. Yield 0.079g

MS: APCI(+ve) 367(+H)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 7.31-6.91(5H, m), 4.66(1H, m), 4.11-4.04(2H, m), 3.70-3.57(10H, m), 2.00-1.95(2H, m), 1.63-1.60(2H, m)

**Examples 3-26**

Examples 3-26 were prepared according to the methods of example 1 or 2 using the appropriate amines.

**Example 3****4-[(4-Chlorophenyl)amino]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile**

MS: APCI(-ve) 315(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.41(1H, bs), 7.66-7.31(4H, 2xd), 3.74-3.64(8H, m)

**Example 4****4-(7-Azabicyclo[2.2.1]hept-7-yl)-6-[(4-chlorophenyl)amino]-1,3,5-triazine-2-carbonitrile**

MS: APCI(-ve) 325(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.37(1H, bs), 7.70-7.35(4H, 2xd), 4.64-4.61(2H, m), 1.74-1.52(8H, m)

**Example 5****4-[(4-Chlorophenyl)amino]-6-pyrrolidin-1-yl-1,3,5-triazine-2-carbonitrile**

5 MS: APCI(-ve) 299(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.29(1H, bs), 7.75-7.36(4H, 2xd), 3.54-3.49(4H, m), 1.96-1.90(4H, m)

**Example 6**

10 **4-[(4-Chlorophenyl)amino]-6-piperidin-1-yl-1,3,5-triazine-2-carbonitrile**

MS: APCI(-ve) 313(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.29(1H, bs), 7.66-7.38(4H, 2xd), 3.74-3.73(4H, m), 1.64-1.55(6H, m)

15

**Example 7****4-[(4-Chlorophenyl)amino]-6-(ethylamino)-1,3,5-triazine-2-carbonitrile**

MS: APCI(-ve) 273(M-1)

20 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.31(1H, bs), 8.39-7.34(5H, m), 3.36-3.27(2H, q), 1.10(3H, t)

**Example 8****4-[(4-Chlorophenyl)amino]-6-(3-hydroxypyrrolidin-1-yl)-1,3,5-triazine-2-carbonitrile**

25 MS: APCI(-ve) 315(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.31(1H, s), 7.76-7.38 (4H, m), 5.06(1H, m), 4.38(1H, m), 3.66-3.45(4H, m), 2.04-1.95(2H, m)

**Example 9**

30 **4-[(4-Chlorophenyl)amino]-6-[(2-piperidin-1-ylethyl)amino]-1,3,5-triazine-2-carbonitrile**

MS: APCI(+ve) 358(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.38(1H, s), 8.35-7.34(5H, m), 3.37(2H, m), 2.43-2.34(6H, m), 1.48-1.44(6H, m)

5

#### Example 10

**4-[(4-Chlorophenyl)amino]-6-(4-phenylpiperidin-1-yl)-1,3,5-triazine-2-carbonitrile**

MS: APCI(-ve) 389(M-1)

10 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.33(1H, bs), 7.68-7.16(9H, m), 4.72-4.69(2H, d), 3.09-2.85(3H, m), 1.88-1.55(4H, m)

#### Example 11

**4-[(3-Chlorobenzyl)amino]-6-(dimethylamino)-1,3,5-triazine-2-carbonitrile**

15

MS: APCI(-ve) 287(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 8.59-8.44(1H, t), 7.37-7.22(4H, m), 4.47-4.44(2H, m), 3.07-3.03(6H, m)

20

#### Example 12

**4-Morpholin-4-yl-6-[(4-morpholin-4-ylphenyl)amino]-1,3,5-triazine-2-carbonitrile**

MS: APCI(+ve) 368(M+1)

25 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.09(1H, s), 7.57-7.48(2H, d), 6.93-6.84(2H, d), 3.72-3.55(12H, m), 3.07-3.00(4H, m)

#### Example 13

30 **4-(2,3-Dihydro-1,4-benzodioxin-6-ylamino)-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile**

MS: APCI(-ve) 339(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.13(1H, s), 7.21-6.80(3H, m), 4.23-3.64(12H, m)

#### Example 14

##### 5 4-Morpholin-4-yl-6-(3-phenylpiperidin-1-yl)-1,3,5-triazine-2-carbonitrile

MS: APCI(+ve) 351(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 7.35-7.22(5H, m), 4.67-2.64(13H, m), 1.93-1.48(4H, m)

#### 10 Example 15

##### 4-(1,4'-Bipiperidin-1'-yl)-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile, trifluoroacetate salt

MS: APCI(+ve) 358(M+1)

15 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.23(1H, bm), 4.75-4.64(2H, m), 3.71-3.36(11H, m), 2.93-2.87(4H, m), 2.08-1.37(10H, m)

#### Example 16

##### 4-[4-(1H-Imidazol-1-yl)piperidin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile

20

MS: APCI(+ve) 341(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.11(1H, s), 7.89-7.88(1H, s), 7.69-7.68(1H, s), 4.79-4.62(3H, m), 3.74-3.02(10H, m), 2.17-1.88(4H, m)

#### 25 Example 17

##### 4-[4-(4-Chlorobenzoyl)piperidin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile

MS: APCI(+ve) 413(M+1)

30 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 8.04-8.02(2H, d), 7.64-7.60(2H, d), 4.62-4.52(2H, m), 3.80-3.69(5H, m), 3.32-3.08(6H, m), 1.87-1.43(4H, m)

**Example 18****4-[4-(5-Chloropyridin-2-yl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile**

5 MS: APCI(+ve) 387(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 8.14-8.13(1H, s), 7.65-7.62(1H, d), 6.91-6.89(1H, d), 3.82-3.57(16H, m)

**Example 19**

10 **4-Morpholin-4-yl-6-[[3-(2-oxopyrrolidin-1-yl)propyl]amino]-1,3,5-triazine-2-carbonitrile**

MS: APCI(+ve) 332(M+1)

15 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 8.10-8.07(1H, t), 3.70-3.62(8H, m), 3.39-3.17(6H, m), 2.22-1.62(6H, m)

**Example 20****1-(4-Cyano-6-morpholin-4-yl-1,3,5-triazin-2-yl)-N,N-diethylpiperidine-3-carboxamide**

20 MS: APCI(+ve) 374(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 4.39(2H, m), 3.78-3.60(4H, m), 3.33-2.63(11H, m), 1.80-1.43(4H, m), 1.16-0.92(6H, m)

**Example 21**

25 **4-[4-(2-Methoxyphenyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile**

MS: APCI(+ve) 382(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 6.99-6.87(4H, m), 3.86-3.63(15H, m), 2.99(4H, m)



**Example 22**

**N~2~(4-Cyano-6-morpholin-4-yl-1,3,5-triazin-2-yl)-N~1~,N~1~bis{4-[N-(4-cyano-6-morpholin-4-yl-1,3,5-triazin-2-yl)-N-isobutylglycyl]morpholin-3-yl}-N~2~isobutylglycinamide**

5

MS: APCI(+ve) 390(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 4.39-4.36(2H, d), 3.62-3.31(18H, m), 2.05-1.92(1H, m), 0.87-0.85(6H, d)

10 **Example 23**

**4-Morpholin-4-yl-6-[(2-pyridin-3-ylethyl)amino]-1,3,5-triazine-2-carbonitrile, trifluoroacetate salt**

MS: APCI(+ve) 312(M+1)

15 

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 8.69-8.64(2H, m), 8.22-8.04(2H, m), 7.78-7.70(1H, m), 3.66-3.53(10H, m), 2.97-2.93(2H, t)

**Example 24**

**4-{[2-(2-Furyl)ethyl]amino}-6-morpholin-4-yl-1,3,5-triazine-2-carbonitrile**

20

MS: APCI(-ve) 299(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 8.21(1H, t), 7.51(1H, s), 6.34(1H, s), 6.15(1H, s), 3.64-3.62(8H, m), 3.52-3.46(2H, m), 2.86-2.82(2H, m)

25 **Example 25**

**4-[(4-Chlorophenyl)amino]-6-(4-methylpiperazin-1-yl)-1,3,5-triazine-2-carbonitrile, trifluoroacetate salt**

MS: APCI(+ve) 330(M+1)

30 

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.56(1H, bs), 10.05(1H, brs), 7.66-7.40(4H, m), 3.41-3.35(8H, m), 2.81(3H, s)

**Example 26****4-Azetidin-1-yl-6-[(4-chlorophenyl)amino]-1,3,5-triazine-2-carbonitrile**

MS: APCI(-ve) 285(M-1)

5 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.32(1H, s), 7.72-7.32(4H, m), 4.15-4.10(4H, m), 2.38-2.30(2H, q)

**Example 27****4-[(4-Chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile**

10

**(i) N-(4-Chlorophenyl)-2,6-difluoropyrimidin-4-amine**

4-Chloroaniline was added to a stirred solution of 2,4,6- trifluoropyrimidine (7.7g), potassium carbonate (7.86g) in ethanol (80ml). The mixture was stirred at room temperature for 16h, diluted with water, extracted with ethyl acetate, dried (MgSO<sub>4</sub>) and  
15 evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with isohexane/ethyl acetate (4:1). Yield 8.3g cream solid

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.47(1H, s), 7.58(2H, d), 7.45(2H, d), 6.35(1H, s)

20 **(ii) 4-[(4-Chlorophenyl)amino]-6-fluoropyrimidine-2-carbonitrile**

Sodium cyanide (0.046g) was added to a solution of the product from step (i) (0.113g) in dimethylsulphoxide (3ml) and stirred at room temperature for 1.5h. The mixture was partitioned between ethyl acetate and water, the organics washed with water, dried (MgSO<sub>4</sub>), and evaporated under reduced pressure. The residue was purified by  
25 chromatography on silica eluting with isohexane/ethyl acetate (4:1). Yield 0.036g

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 10.56(1H, s), 7.57(2H, d), 7.47(2H, d), 6.65(1H, s)

**(iii) 4-[(4-Chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile**

30 Morpholine (0.16g) was added to a solution of the product from step (ii) (0.16g) in isopropylalcohol (4ml) and stirred for 2h at room temperature. The mixture was partitioned between ethyl acetate and aqueous sodium hydrogencarbonate solution, the organics separated, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with isohexane/ethyl acetate (1:1). Yield  
35 0.09g

MS: APCI(+ve) 316(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.65(1H, s), 7.52(2H, d), 7.38(2H, d), 6.08(1H, s), 3.67(4H, t), 3.48(2H, t)

5    **Examples 28-42**

Examples 28-42 were prepared according to the general method of example 27 using the appropriate amines or phenols

**Example 28**

10    **4-[(4-Methylcyclohexyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile**

MS: APCI(+ve) 302(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 7.21-7.18(1H, d), 5.83(1H, s), 3.89(1H, bs), 3.88(4H, m), 3.41(4H, m), 1.63-1.28(9H, m), 0.89(3H, d)

15

**Example 29**

**4-(4-Chlorophenoxy)-6-morpholin-4-ylpyrimidine-2-carbonitrile**

MS: APCI(-ve) 315(M-1)

20    <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 7.53-7.20(4H, 2xd), 6.63(1H, s), 3.65-3.63(8H, m)

**Example 30**

**4-[(4-Chlorophenyl)amino]-6-(dimethylamino)pyrimidine-2-carbonitrile**

25    MS: APCI(+ve) 274(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.57(1H, s), 7.55-7.34(4H, 2xd), 5.93(1H, s), 3.02(6H, m)

**Example 31**

30    **4-[(1-Methylpiperidin-4-yl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile, trifluoroacetate salt**

MS: APCI(+ve) 303(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.36(1H, brs), 7.49-7.47(1H, d), 5.76(1H, s), 3.92(1H, bm), 3.67-3.43(8H, 2xm), 3.34-3.10(4H, m), 2.75(3H, s), 2.07-1.68(4H, m)

5 **Example 32**

**4-(Cyclohexylamino)-6-morpholin-4-ylpyrimidine-2-carbonitrile**

MS: APCI(+ve) 288(M+1)

10 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 7.23-7.21(1H, d), 5.73(1H, s), 3.62-3.42(9H, m), 1.83-1.07(10H, m)

**Example 33**

**4-[(4-Chlorophenyl)amino]-6-pyrrolidin-1-ylpyrimidine-2-carbonitrile**

15 MS: APCI(+ve) 300(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.55(1H, s), 7.54-7.35(4H, 2xd), 5.79(1H, s), 3.38(4H, m), 1.93(4H, m)

**Example 34**

20 **4-[(6-Chloropyridin-3-yl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile**

MS: APCI(-ve) 315(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.83(1H, s), 8.55-8.49(1H, s), 8.06-8.02(1H, d), 7.49-7.46(1H, d), 6.10(1H, s), 3.69-3.66(4H, m), 3.52-3.48(4H, m)

25

**Example 35**

**1-{6-[(4-Chlorophenyl)amino]-2-cyanopyrimidin-4-yl}-L-prolinamide**

MS: APCI(+ve) 343(M+1)

30 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.33(1H, s), 7.57-7.24(4H, 2xd), 7.00(2H, bm), 5.81(1H, s), 4.31-3.38(3H, m), 2.26-1.26(4H, m)

**Example 36**

**4-(4-Aminopiperidin-1-yl)-6-[(4-chlorophenyl)amino]pyrimidine-2-carbonitrile, trifluoroacetate salt**

5

MS: APCI(+ve) 329(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.66(1H, s), 7.88-7.36(7H, m), 6.15(1H, s), 4.23-4.20(2H, m), 3.17-2.96(3H, m), 1.98-1.38(4H, m)

10 **Example 37**

**4-[(4-Chlorophenyl)amino]-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidine-2-carbonitrile, acetate salt**

MS: APCI(+ve) 383(M+1)

15 

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.57(1H, s), 7.53-7.35(4H, 2xd), 6.09(1H, s), 4.06-2.51(9H, m), 1.92-1.90(5H, m), 1.74-1.34(6H, m)

**Example 38**20 

**4-[(4-Chlorophenyl)amino]-6-[(3-pyrrolidin-1-ylpropyl)amino]pyrimidine-2-carbonitrile, trifluoroacetate salt**

MS: APCI(+ve) 357(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.52(2H, m), 7.63-7.36(5H, 2xd+m), 5.92(1H, bs), 3.54-2.99(8H, m), 2.00-1.84(6H, m)

25

**Example 39**

**tert-Butyl 4-{6-[(4-chlorophenyl)amino]-2-cyanopyrimidin-4-yl}piperazine-1-carboxylate**

30 

MS: APCI(+ve) 415(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.66(1H, s), 7.52(2H, d), 7.37(2H, d), 6.07(1H, s), 3.54-3.51(4H, m), 3.44-3.41(4H, m), 1.42(9H, s)

**Example 40****4-[(4-Chlorophenyl)amino]-6-(cyclopropylamino)pyrimidine-2-carbonitrile**

MS: APCI(+ve) 286(M+1)

5 1H NMR: (DMSO-d<sub>6</sub>) δ 9.65(1H, s), 7.80(1H, s), 7.53(2H, d), 7.37(2H, d), 6.08(1H, s), 0.76-0.71(2H, m), 0.50-0.46(2H, m)

**Example 41****4-[(4-Chlorophenyl)amino]-6-piperazin-1-ylpyrimidine-2-carbonitrile**

10

MS: APCI(+ve) 315(M+1)

1H NMR: (DMSO-d<sub>6</sub>) δ 9.62(1H, s), 7.53(2H, d), 7.37(2H, d), 6.07(1H, s), 3.46(4H, t), 2.79(4H, t)

15 **Example 42**

(2S)-N~2~-{6-[(4-Chlorophenyl)amino]-2-cyanopyrimidin-4-yl}-N~1~,N~1~-bis[4-(N-{6-[(4-chlorophenyl)amino]-2-cyanopyrimidin-4-yl}-L-leucyl)morpholin-3-yl]-L-leucinamide

20 

MS: APCI(+ve) 429(M+1)

1H NMR: (DMSO-d<sub>6</sub>) δ 9.51(1H, s), 7.82(1H, d), 7.46(2H, d), 7.37(2H, d), 6.09(1H, s), 4.87(1H, s), 3.67-3.47(6H, m), 3.35-3.25(2H, m), 1.66-1.53(2H, m), 1.48-1.39(1H, m), 0.92-0.89(6H, m)

25 **Example 43****5-Chloro-4-[(4-chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile****(i) 4-(5-Chloro-2,6-difluoropyrimidin-4-yl)morpholine**

30 Morpholine (0.774mg) was added to a solution of 5-chloro-2,4,6-trifluoropyrimidine (1.5g), N,N-diisopropylethylamine (1.15g) in 1,4-dioxane (30ml) and stirred at room temperature for 16h. The mixture was partitioned between ethyl acetate and water, the organic layer dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was

purified by chromatography on silica eluting with 8% ethyl acetate in isohexane. Yield 0.88g

**(ii) 5-Chloro-N-(4-chlorophenyl)-2-fluoro-6-morpholin-4-ylpyrimidin-4-amine**

5 4-Chloroaniline (1.44g) was added to a solution of the product from step (i) (0.88g) and N,N-diisopropylethylamine (0.484g) in 1,4-dioxane (15ml) and isopropylalcohol (15ml) and the mixture heated at 110°C for 6 days. The mixture was partitioned between ethyl acetate and water, the organics dried (MgSO<sub>4</sub>), and evaporated under reduced pressure. The solid was triturated with ethyl acetate, filtered and the filtrate purified by  
10 chromatography on silica eluting with 3% ethyl acetate in toluene. Yield 0.28g

MS: APCI(+ve) 343/5(M+1)

**(iii) 5-Chloro-4-[(4-chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile**

15 Sodium cyanide (0.057g) was added to a solution of the product from step (ii) (0.2g) in dimethylsulphoxide (5ml) and the mixture stirred at room temperature. After 18h, the mixture was partitioned between ethyl acetate and water, the organics separated, washed with water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 5% ethyl acetate in toluene. Yield 0.09g

20

MS: APCI(-ve) 348(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.34(1H, s), 7.53(2H, d), 7.42(2H, d), 3.71(4H, t), 3.55(4H, t)

**Example 44**

25 **4-[(4-Chlorophenyl)amino]-5-methoxy-6-piperazin-1-ylpyrimidine-2-carbonitrile, trifluoroacetate salt**

**(i) 5-Methoxy-2-thioxodihydropyrimidine-4,6(1H,5H)-dione**

Thiourea (24g) and methoxymethyl malonate (34g) was added to a solution of sodium  
30 (12g) in methanol and the mixture heated under reflux for 10h. The methanol was evaporated under reduced pressure, water (500ml) added and extracted with ether. The aqueous layer was acidified to pH1 with conc. hydrochloric acid, evaporated to ~200ml and the precipitate filtered and dried. Yield 23g

35 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 11.31(2H, s), 3.48(3H, s)

**(ii) 2-(Ethylthio)-5-methoxypyrimidine-4,6(1H,5H)-dione**

Ethyl iodide (11.2ml) was added dropwise to a stirred mixture of the product from step (i) (23g) and sodium hydroxide (6g) in water (400ml). After 16h the mixture was filtered, the filtrate acidified to pH1 and the precipitate filtered, washed with water and dried. Yield 17.8g

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 12.25(1H, s), 3.59(3H, s), 3.57(1H, s), 3.06(2H, q), 1.28(3H, t)

**(iii) 4,6-Dichloro-2-(ethylthio)-5-methoxypyrimidine**

A mixture of the product from step (ii) (17.8g) and N,N-diethylaniline (20ml) in phosphorus oxychloride (400ml) was heated at 100°C for 3h. The excess reagent was removed under reduced pressure and the residue poured onto ice and extracted with ether. The ether layer was washed with water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 5% ethyl acetate in isohexane. Yield 12.8g

**(iv) 6-Chloro-N-(4-chlorophenyl)-2-(ethylthio)-5-methoxypyrimidin-4-amine**

A solution of the product from step (iii) (4g) and 4-chloroaniline (5.3g) in ethanol (40ml) was heated under reflux for 16h then the solvent removed under reduced pressure. The residue was partitioned between ethyl acetate and 2M hydrochloric acid, the organics washed with water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by chromatography on silica eluting with 10-15% ethyl acetate in isohexane. Yield 4.99 g

MS: APCI(+ve) 330/2(M+1)

**(v) 4-Chloro-6-[(4-chlorophenyl)amino]-5-methoxypyrimidine-2-carbonitrile**

A mixture of the product from step (iv) (4.9g) and 3-chloroperoxybenzoic acid (10g, Aldrich 77% max.) in dichloromethane (150ml) was stirred at room temperature for 3h, washed with aqueous sodium metabisulphite solution, water, aqueous sodium hydrogencarbonate solution, water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The solid was dissolved in dimethylsulphoxide (40ml), sodium cyanide (1.1g) added and stirred for 2h at room temperature. The mixture was partitioned between ethyl acetate and water, the organics dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue



was purified by chromatography on silica eluting with 30% ethyl acetate in isohexane.

Yield 3.23g

MS: APCI(+ve) 295/7(M+1)

(vi) 4-[(4-Chlorophenyl)amino]-5-methoxy-6-piperazin-1-ylpyrimidine-2-carbonitrile

A solution of the product from step (v) (0.25g) and piperazine (0.366g) in tetrahydrofuran (8ml) was heated at 60°C for 6h then the solvent removed under reduced pressure. The residue was purified by RPHPLC 15-75% acetonitrile in aqueous trifluoroacetic acid.

Yield 0.139g

MS: APCI(+ve) 345(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.29(1H, s), 8.92(2H, s), 7.67(2H, d), 7.40(2H, d), 3.83-3.80(4H, m), 3.69(3H, s), 3.25-3.23(4H, m)

Mpt 230°C

#### Examples 45-51

Examples 45-51 were prepared according to the method of example 44 using the appropriate amines

#### Example 45

4-[(4-Chlorophenyl)amino]-5-methoxy-6-morpholin-4-ylpyrimidine-2-carbonitrile

MS: APCI(+ve) 346(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.20(1H, s), 7.67(2H, d), 7.38(2H, d), 3.73-3.70(4H, m), 3.68(3H, s), 3.63-3.61(4H, m)

Mpt 176°C

#### Example 46

4-[(3S)-3-Aminopyrrolidin-1-yl]-6-[(4-chlorophenyl)amino]-5-methoxypyrimidine-2-carbonitrile, trifluoroacetate salt

MS: APCI(+ve) 345/7(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.12(1H, s), 8.10(3H, s), 7.66(2H, d), 7.38(2H, d), 3.91-3.69(5H, m), 3.65(3H, s), 2.33-2.22(1H, m), 2.08-2.01(1H, m)  
Mpt 345-7°C

5    **Example 47**

**4-[(4-Chlorophenyl)amino]-6-{4-[3-(dimethylamino)propyl]piperazin-1-yl}-5-methoxypyrimidine-2-carbonitrile, bis-trifluoroacetate salt**

MS: APCI(+ve) 430/2(M+1)

10    <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) 90°C δ 8.94(1H, s), 7.64(2H, d), 7.35(2H, d), 3.81(4H, brs), 3.70(3H, s), 3.15-3.09(2H, m), 3.00(4H, brs), 2.86(2H, brs), 2.81(6H, s), 2.03-1.95(2H, m)  
Mpt 210-2°C

**Example 48**

15    **4-[(4-Chlorophenyl)amino]-6-(dimethylamino)-5-methoxypyrimidine-2-carbonitrile**

MS: APCI(-ve) 302/4(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) 90°C δ 9.08(1H, s), 7.66(2H, d), 7.37(2H, d), 3.62(3H, s), 3.13(6H, s)  
20    Mpt 173°C

**Example 49**

**4-[(4-Chlorophenyl)amino]-5-methoxy-6-(3-oxopiperazin-1-yl)pyrimidine-2-carbonitrile**

25

MS: APCI(-ve) 357/9(M-1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.24(1H, s), 8.10(1H, s), 7.67(2H, d), 7.39(2H, d), 4.17(2H, s), 3.85-3.83(2H, m), 3.66(3H, s), 3.32-3.29(2H, m)  
Mpt 244°C

30

**Example 50****1-{6-[(4-Chlorophenyl)amino]-2-cyano-5-methoxypyrimidin-4-yl}piperidine-3-carboxamide**

5 MS: APCI(+ve) 387/9 (M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.16(1H, s), 7.68(2H, d), 7.40-7.35(3H, m), 6.89(1H, s), 4.34-4.25(2H, m), 3.65(3H, s), 3.07-2.92(2H, m), 2.35-2.40(1H, m), 1.90-1.51(4H, m)

**Example 51**

10 **4-(4-Aminopiperidin-1-yl)-6-[(4-chlorophenyl)amino]-5-methoxypyrimidine-2-carbonitrile, trifluoroacetate salt**

MS: APCI(+ve) 359/61 (M+1)

15 <sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 9.20(1H, s), 7.93(3H, s), 7.67(2H, d), 7.39(2H, d), 4.36-4.32(2H, m), 3.66(3H, s), 3.08-3.01(2H, m), 2.00-1.97(2H, m), 1.57-1.54(2H, m)

**Example 52****5-Amino-4-[(4-chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile**

- 20 (i) N-(4-Chlorophenyl)-6-morpholin-4-yl-5-nitro-2-(propylthio)pyrimidin-4-amine  
Morpholine (1.31 ml) was added dropwise to a stirred solution of 4,6-dichloro-5-nitro-2-thiopropyl pyrimidine (4g), N,N-diisopropylamine (7ml) in dichloromethane (50ml) at 0°C. After 1h, 4-chloroaniline (1.9g) was added, the mixture stirred at room temperature for 24h, then heated under reflux for 24h. The mixture was partitioned between  
25 dichloromethane and 2M hydrochloric acid, the organics washed with water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. Yield 5g

MS: APCI(+ve) 410/2 (M+1)

- 30 (ii) 4-[(4-Chlorophenyl)amino]-6-morpholin-4-yl-5-nitropyrimidine-2-carbonitrile  
A mixture of the product from step (i) (5g) and 3-chloroperoxybenzoic acid (12g, Aldrich 77% max.) in dichloromethane (200ml) was stirred at room temperature for 2h, washed with aqueous sodium metabisulphite solution, water, aqueous sodium hydrogencarbonate solution, water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The solid was

dissolved in dimethylsulphoxide (30ml), sodium cyanide (2g) added and stirred for 1h at room temperature. Water (500ml) was added and the solid filtered, washed with water, dried and the residue triturated with ether. Yield 1.7g

5 MS: APCI(+ve) 361/3 (M+1)

**(iii) 5-Amino-4-[(4-chlorophenyl)amino]-6-morpholin-4-ylpyrimidine-2-carbonitrile**

The product from step (ii) (1.7g) and 10% palladium on charcoal (0.2g) in ethyl acetate (300ml) was hydrogenated at 2Bar for 8h, filtered through celite and the solvent  
10 evaporated under reduced pressure. Yield 1.05g

MS: APCI(+ve) 329/331 (M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 8.66(1H, s), 7.62(2H, d), 7.39(2H, d), 5.53(2H, s), 3.78-3.76(4H, m), 3.08-3.06(4H, m)

15 Mpt 253-4°C

**Example 53**

**5-Amino-4-[(4-Chlorophenyl)amino]-6-(ethylamino)pyrimidine-2-carbonitrile**

Example 53 was prepared according to the general method of example 52 using the  
20 appropriate amine

MS: APCI(+ve) 289/91(M+1)

<sup>1</sup>H NMR: (DMSO-d<sub>6</sub>) δ 8.19(1H, s), 7.50(2H, d), 7.31(2H, d), 6.52(1H, t), 5.20(2H, s), 3.41-3.35(2H, m), 1.18(3H, t)

25 Mpt 211-2°C

**Measurement of Cathepsin S activity.**

QFRET Technology (Quenched Fluorescent Resonance Energy Transfer) was used to measure the inhibition by test compounds of Cathepsin S-mediated cleavage of the synthetic peptide Z-Val-Val-Arg-AMC. Compounds were screened at five concentrations in duplicate and the pIC<sub>50</sub> values reported.

Synthetic substrate, 20μM [final]Z-Val-Val-Arg-AMC in phosphate buffer were added to a 96 well black Optiplate. The assay plates were pre-read for compound auto fluorescence on SpectraMax Gemini at 355nM excitation and 460nM emission. 250pM [final] rHuman Cathepsin S in phosphate buffer was added and incubated for 2h at room temperature on the SpectraMax Gemini, taking readings every 20min at 355nM excitation and 460nM emission.

Activity Based template (5PTB-8) used the auto fluorescent corrected data to calculate the percentage inhibition for each compound concentration using the relevant plate controls. This data was used to construct inhibition curves and pIC<sub>50</sub> estimated by non-linear regression using a 4 parameter logistic model.